CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) for non-muscle invasive bladder cancer (NMIBC) demonstrated a 75% complete response rate at any time, with 46% at 12 months and 42% at 24 months in recent trials. The drug also showed a best-in-class safety profile with no severe (Grade 3 or higher) adverse events reported. The company plans to complete a rolling Biologics License Application (BLA) by the fourth quarter of 2026, with multiple clinical trial results expected in the second half of 2026 and 2027. This progress has driven CG Oncology's shares up over 150% in the past year, reflecting strong investor confidence in the drug's potential.
Yvonne Wassenaar, a director at Rubrik, sold 721 shares at a price of $75 each just before the company's stock experienced a significant rally. This sale occurred ahead of the stock's upward movement, which may be of interest to investors tracking in...
Alphabet's $900 million investment in SpaceX in 2015 has grown to a $94.2 billion stake as of mid-2026, marking a rare 100x return. This stake now represents 95% of Alphabet's investment portfolio and highlights the company's willingness to make long...
SpaceX shares opened above IPO price but early investors faced losses as the stock dipped after debut. Despite a recent rally nearing 40%, initial buyers still saw declines. Positive earnings and strategic investments, including Tesla's stake in a Te...
Tom Bruni and Sid Mokhtari discuss the current US and Canadian market trends, highlighting a broadening market and sector rotation that supports the S&P 500's bull market despite tech leadership fading. The S&P/TSX Composite Index outperforms due to ...
The SEI Enhanced US Large Cap Value ETF (SEIV) has earned a 'buy' rating due to its multi-factor investment approach and recent strong performance compared to peers. It features a forward price-to-earnings ratio of 11.01x and an expected earnings gro...
